A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Clinical trial NCT04975308 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04975308
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-04
- Primary completion
- 2024-06-24
- Enrollment
- 874
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.